EUVIMEDEUVIMED entdecken
Open Access

Candida guilliermondii fungemia: a 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center

Jack W McHugh iD, David R Bayless, Nischal Ranganath iD, Ryan W Stevens, Dalton R Kind, Nancy L Wengenack iD, Aditya S Shah

Journal of Clinical Microbiology · 13.11.2024 · 62 (11)

DOI: 10.1128/jcm.01057-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Microbiology, erschienen am 13.11.2024. Verfasst von Jack W McHugh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Tertiary Care Centers, Candida, Microbial Sensitivity Tests. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of invasive candidiasis caused by non- albicans Candida species is increasing. Candida guilliermondii is an infrequent cause of candidemia but has been associated with decreased susceptibility to triazoles. Clinical data related to the infection with C. guilliermondii are sparse. Our study evaluated the antifungal susceptibility testing (AST) for C. guilliermondii isolates submitted to a reference laboratory over a 12-year period (2012–2023). AST patterns were examined using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cutoff values (ECVs) and breakpoints. Where isolates were identified from patients treated at our institution, retrospective chart review was performed to describe patient risk factors, treatment approaches, and outcomes associated with C. guilliermondii fungemia. One hundred twelve blood culture isolates of C. guilliermondii were identified, and clinical data were available for 21 fungemic patients. A significant number of isolates (9.8–20.5%) were observed to be non-wild type for various triazoles. All isolates were susceptible to micafungin. A majority (76.2%) of cases of C. guilliermondii fungemia treated at our tertiary care center were hospital-acquired, and two-thirds of patients were immunocompromised at the time of diagnosis. Ten of the 21 patients died within 60 days of fungemia, although mortality was directly or partially attributed to C. guilliermondii fungemia in only four cases (19.0%). Echinocandins may be used for empiric therapy for C. guilliermondii until the results of AST are available. Further research is required to determine appropriate clinical breakpoints for triazoles. IMPORTANCE Our study addresses a significant knowledge gap in the clinical management of this non- Candida albicans species. Our retrospective review includes comprehensive AST data for 112 Candida guilliermondii isolates, which is the largest number of isolates reported from the United States to date. Susceptibility data are supplemented by clinical outcomes, where isolates were identified for patients treated at Mayo Clinic. Key findings from our study include the observation that a notable proportion of C. guilliermondii isolates exhibit non-wild-type profiles for various triazoles. Importantly, all isolates remained susceptible to echinocandins, suggesting their efficacy as first-line therapy in the absence of timely susceptibility results. Furthermore, our study highlights the high mortality associated with C. guilliermondii fungemia in immunocompromised patients, emphasizing the urgent need for optimized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsTertiary Care CentersCandidaMicrobial Sensitivity TestsCandidemiaHumansRetrospective StudiesFemaleMaleMiddle AgedAgedAdultAged, 80 and overYoung AdultRisk FactorsAdolescentDrug Resistance, Fungal

Stichwörter der Autor:innen

Candidaantifungal susceptibility testingfungiimmunocompromised hosts

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pharmacy Services, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Clinical Microbiology, Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Jack W McHugh, Nischal Ranganath, Nancy L Wengenack

Zitieren

APA

McHugh, J. W., Bayless, D. R., Ranganath, N., Stevens, R. W., Kind, D. R., Wengenack, N. L., & Shah, A. S. (2024). Candida guilliermondii fungemia: a 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center. Journal of Clinical Microbiology, 62(11). https://doi.org/10.1128/jcm.01057-24

Vancouver

McHugh JW, Bayless DR, Ranganath N, Stevens RW, Kind DR, Wengenack NL, et al. Candida guilliermondii fungemia: a 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center. Journal of Clinical Microbiology. 2024;62(11). doi:10.1128/jcm.01057-24

BibTeX
@article{McHugh2024,
  author = {McHugh, Jack W and Bayless, David R and Ranganath, Nischal and Stevens, Ryan W and Kind, Dalton R and Wengenack, Nancy L and Shah, Aditya S},
  title = {Candida guilliermondii fungemia: a 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center},
  journal = {Journal of Clinical Microbiology},
  year = {2024},
  volume = {62},
  number = {11},
  doi = {10.1128/jcm.01057-24}
}
Kostenlos starten →